Table 5 Summary of the results of the meta-analysis of the association of APOB gene polymorphisms and hyperlipidemia

APOB MspI

A

M- vs M+

0.0%/ 0.731

0.892(0.756 ~ 1.053)

0.178

0.452

D

M-M−/M + M- Vs M + M+

0.0%/0.716

0.868(0.716 ~ 1.053)

0.152

0.707

R

M-M-vs M + M−/M + M+

0.0%/ 0.513

0.932(0.596 ~ 1.456)

0.757

0.908

C

M-M- vs M + M+

0.0%/ 0.555

0.903(0.574 ~ 1.421)

0.660

0.883

M + M- vs M + M+

0.0%/ 0.654

0.864(0.705 ~ 1.057)

0.156

0.746

APOB XbaI

A

T vs C

72.4%/ < 0.001

1.444(1.061 ~ 1.966)

0.020

0.732

D

TT + CT vs CC

73.5%/ < 0.001

1.360(0.943 ~ 1.962)

0.100

0.945

R

TT vs CT + CC

0.0%/ 0.747

1.613(1.022 ~ 2.545)

0.040

0.707

C

TT vs CC

0.0%/ 0.774

1.432(0.851 ~ 2.411)

0.017

0.724

CT vs CC

73.5%/ < 0.001

1.322(0.912 ~ 1.917)

0.140

0.837

APOB EcorI

A

A vs G

70.0%/ < 0.001

1.333(0.942 ~ 1.885)

0.104

0.474

D

AA+AG Vs GG

72.9%/ < 0.001

1.366(0.924 ~ 2.020)

0.118

0.283

R

AA vs AG + GG

0.0%/ 0.942

1.183(0.628 ~ 2.229)

0.603

0.221

C

AA vs GG

0.0%/ 0.886

1.166(0.617 ~ 2.202)

0.637

0.086

AG vs GG

72.6%/ < 0.001

1.356(0.913 ~ 2.015)

0.131

0.371